-
1.发明公开TARGETING OF MELANOCYTES FOR DELIVERING THERAPEUTIC OR DIAGNOSTIC AGENTS USING PROTEIN NANOCAGES 审中-公开靶向使用蛋白质纳米颗粒提供治疗或诊断剂的黑色素细胞
公开(公告)号：EP3197920A1
公开(公告)日：2017-08-02
申请号：EP15843793.9
申请日：2015-09-25
IPC分类号： C07K19/00 , A61K47/42 , C07K14/32 , A61K38/34 , C07K14/68 , C07K14/695 , A61K39/395 , C07K17/06 , A61P35/00 , A61P43/00
CPC分类号： A61K38/34 , A61K9/0014 , A61K38/35 , C07K14/195 , C07K14/32 , C07K14/47 , C07K14/685 , C07K14/69 , C07K14/695 , C07K14/723
摘要： The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions. In the preferred embodiment, the protein nanocage is composed of Bacillus stearothermophilus E2 protein of pyruvate dehydrogenase multi-enzyme complex (E2), with a skin penetrating and cell permeating SPACE moiety, and a melanocyte-targeting moeity of alpha melanocyte stimulating hormone.
摘要翻译： 本发明涉及包含黑素细胞靶向部分的蛋白质纳米笼和包含该蛋白笼的药物组合物以及使用该蛋白质纳米笼或药物组合物治疗或诊断色素沉着过度病症或其他黑素细胞相关病症的方法。 在优选实施方案中，蛋白质纳米笼由丙酮酸脱氢酶多酶复合物（E2）的嗜热脂肪芽孢杆菌E2蛋白，具有皮肤穿透和细胞渗透SPACE部分以及黑素细胞靶向部分的α黑素细胞刺激激素组成。
-
2.发明公开Adrenocorticotropic hormone analogs and related methods 审中-公开Analoga des adrenocorticotropen Hormons und entsprechende Verfahren
公开(公告)号：EP2446894A2
公开(公告)日：2012-05-02
申请号：EP11185682.9
申请日：2005-10-27
发明人： Brennan, Miles B. , Dores, Robert M. , Haskell-Luevano, Carrie , Hochgeschwender, Ute H. , Costa, Jessica I.
CPC分类号： C07K14/695 , A61K38/00
摘要： ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.
摘要翻译： 本发明的ACTH类似物包括具有一个或多个结构修饰的ACTH肽序列的化合物，其可以具有以下优选的ACTH类似生物学功能中的一种或多种：（1）在存在下，肾上腺皮质激素分泌物减少 ACTH类似物与未经修饰的ACTH相比，（2）在内源性ACTH存在下肾上腺皮质类固醇分泌减少;（3）与未修饰的ACTH结合MC相比，MC-2R受体活化降低MC-2R结合亲和力增加 -2R黑皮质素。 因此，本发明的ACTH类似物化合物可用于治疗或预防与ACTH，ACTH受体或皮质类固醇分泌相关的疾病和病症，例如早产和库兴氏病。
-
公开(公告)号：EP1363658A2
公开(公告)日：2003-11-26
申请号：EP02714031.8
申请日：2002-02-19
发明人： WITTIG, Burghardt , STEIN, Christoph , SCHÄFER, Michael , SCHROFF, Matthias , JUNGHANS, Claas , KÖNIG MEREDIZ, Sven Andres
IPC分类号： A61K38/33
CPC分类号： A61K38/33 , A61K38/35 , A61K48/00 , A61K48/0075 , A61K2039/53 , C07K14/57509 , C07K14/665 , C07K14/675 , C07K14/69 , C07K14/695 , C07K2319/00
摘要： The invention relates to an agent for calming the sensation of pain, in particular in chronic inflammatory disorders, by the expression of endogenic, neuroendocrine peptides at the inflammation site. The invention relates in particular to the expression of POMC or CRF from locally injected DNA expression constructs, preferably covalently peptide-modified expression constructs.
-
公开(公告)号：EP1305338A2
公开(公告)日：2003-05-02
申请号：EP01957662.8
申请日：2001-08-02
发明人： GRAVEL, Denis , HABI, Abdelkrim , ABRIBAT, Thierry
IPC分类号： C07K14/605 , C07K14/00 , C07K14/47 , A61K38/04 , C07K14/635 , C07K14/655
CPC分类号： C07K14/6555 , A61K38/00 , C07K7/086 , C07K7/23 , C07K14/00 , C07K14/47 , C07K14/55 , C07K14/575 , C07K14/57509 , C07K14/57545 , C07K14/58 , C07K14/585 , C07K14/595 , C07K14/60 , C07K14/605 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/675 , C07K14/68 , C07K14/695 , C07K14/78
摘要： The present invention is concerned with modified biological peptides providing increased potency, prolonged activity and/or increased half-life thereof. The modification is made via coupling through an amide bond with at least one conformationally rigid substituent, either at the N-terminal of the peptide, the C-terminal of the peptide, on a free amino or carboxyl group along the peptide chain, or at a plurality of these sites. Those peptides exhibit clinical usefulness for example in treating states of insulin resistance associated with pathologies such as type II diabetes.
-
公开(公告)号：EP0679092B1
公开(公告)日：1999-04-28
申请号：EP95902487.8
申请日：1994-11-09
发明人： SUTO, Mark, J. , GIRTEN, Beverly, E. , HOUGHTEN, Richard, A. , LOULLIS, Costas, C. , TUTTLE, Ronald, R.
CPC分类号： A61K38/08 , C07K5/1024 , C07K14/68 , C07K14/685 , C07K14/695
摘要： The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.
-
公开(公告)号：EP0679092A1
公开(公告)日：1995-11-02
申请号：EP95902487.0
申请日：1994-11-09
发明人： SUTO, Mark, J. , GIRTEN, Beverly, E. , HOUGHTEN, Richard, A. , LOULLIS, Costas, C. , TUTTLE, Ronald, R.
CPC分类号： A61K38/08 , C07K5/1024 , C07K14/68 , C07K14/685 , C07K14/695
摘要： The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.
-
7.发明公开USE OF $g(b)-CELL-TROPIN (ACTH 22-39) ANTAGONISTS IN THE TREATMENT OF TYPE II DIABETES AND ASSOCIATED DISEASES 失效使用β-CELL-调理素（ACTH 22-39）antagoniste II型糖尿病和相关疾病的治疗。
公开(公告)号：EP0671949A1
公开(公告)日：1995-09-20
申请号：EP92913704.0
申请日：1992-06-16
CPC分类号： C07K14/695 , A61K38/00 , C07K16/26
摘要： Pharmaceuticals, including compounds and compositions and the use of such pharmaceuticals in the treatment of Type II diabetes and conditions associated with type II diabetes.
-
8.发明公开PROCESS FOR PRODUCING PEPTIDES BY SPECIFIC CLEAVAGE OF FUSION PROTEINS WITH COLLAGENASES OBTAINED BY GENETIC ENGINEERING 无效用于生产肽用拼贴NOSE Sa基因得到融合蛋白的具体分裂。
公开(公告)号：EP0393039A1
公开(公告)日：1990-10-24
申请号：EP88907257.0
申请日：1988-08-29
CPC分类号： C07K14/695 , C07K2319/00 , C07K2319/50 , C12N15/62 , C12N15/66
摘要： Sont décrites des protéines de fusion ayant la formule (I): H2N-Z1-X-(Pro-Y-Gly)n-Pro-Z2-COOH, dans laquelle n 2, X et Y représentent chacun des 20 acides aminés déterminés par le code génétique, Z1 est une séquence d'acides aminés bactériens et Z2 est le peptide cible composé de n'importe quels acides aminés voulus du code génétique. Leur procédé de production et leur clivage enzymatique, afin de former les protéines eucariotiques désirées, sont également décrits.
-
9.发明公开Pharmaceutical compositions containing ACTH fragments for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies 失效含有ACTH片段的药物组合物用于冲击症和呼吸道感染和心脏不良症的治疗
公开(公告)号：EP0232697A3
公开(公告)日：1990-05-23
申请号：EP87100016.2
申请日：1987-01-02
申请人： Bertolini, Alfio
发明人： Bertolini, Alfio
CPC分类号： A61K38/35 , A61K38/34 , C07K14/695
摘要： The parenteral administration of 8O-16O µg per kg body weight of substituted or unsubstituted fragments of ACTH (1-39) having formula ACTH (X-Y) wherein X is an integer from 1 to 5 and Y is an integer from 1O to 39 (provided that, when X is 1, Y is not 24) restores the normal blood pressure and respiratory frequence in a patient in serious shock conditions, particularly in hypovolemic shock.
-
10.发明公开CHIMERIC PEPTIDES FOR NEUROPEPTIDE DELIVERY THROUGH THE BLOOD-BRAIN BARRIER 失效嵌合肽用于神经肽通过血 - 脑LIMIT供应。
公开(公告)号：EP0276278A1
公开(公告)日：1988-08-03
申请号：EP87905071.0
申请日：1987-07-16
CPC分类号： C07K1/1075 , A61K38/00 , A61K47/62 , C07K7/16 , C07K14/62 , C07K14/655 , C07K14/675 , C07K14/695 , Y10S930/15 , Y10S930/16 , Y10S930/26
摘要： Les peptides chimériques décrits sont adaptés pour fournir des agents neuropharmaceutiques tels que des neuropeptides au cerveau par transcytose par l'intermédiaire d'un récepteur au travers de la barrière hémato-encéphalique. Les peptides chimériques comprennent un peptide qui est capable par lui-même de traverser la barrière hémato-encéphalique par transcytose à une vitesse relativement élevée. Le peptide transportable est conjugué à un neuropeptide hydrophyle qui est par lui-même transportable uniquement à une très faible vitesse dans le cerveau au travers de la barrière hémato-encéphalique. Le peptide chimérique résultant est transporté dans le cerveau à une vitesse beaucoup plus élevée que le neuropeptide seul, ceci dans le but de disposer de moyens efficaces pour introduire des neuropeptides hydrophyles dans le cerveau au travers de la barrière hémato-encéphalique.
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.019 秒)
